A Phase I/IIa, Multicenter, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics of ICP-192 in Patients With Advanced Solid Malignancies

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 31 Jan 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Gunagratinib (Primary)
Indications Biliary cancer; Cholangiocarcinoma; Gastric cancer; Head and neck cancer; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors InnoCare Pharma

25 Jan 2023 According to InnoCare Pharma Media Release, data from this study was presented at 2023 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium.
25 Jan 2023 Results published in the InnoCare Pharma Media Release
21 Jan 2023 Results(n=18 from phase IIa dose-expansion study) assessing the efficacy and safety of of gunagratinib in patients with cholangiocarcinoma presented at the 2023 Gastrointestinal Cancers Symposium

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com